Skip to main content
Clinical Trials/NCT00713349
NCT00713349
Completed
Phase 2

A Randomized, Evaluator Blinded, Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing of Induced Thermal Wounds

Healthpoint1 site in 1 country25 target enrollmentJune 2008

Overview

Phase
Phase 2
Intervention
Placebo comparator
Conditions
Wounds
Sponsor
Healthpoint
Enrollment
25
Locations
1
Primary Endpoint
Complete Wound Closure
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The objective of the study is to compare the healing of wounds induced by cryo-injury when treated with white petrolatum versus an ointment vehicle.

Registry
clinicaltrials.gov
Start Date
June 2008
End Date
September 2008
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects will be considered qualified for enrollment if they:
  • Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks and contact information.
  • Are male or female, ≥ 18 years of age, of any race.
  • Are willing to attend all required study visits, and to comply with study procedures.
  • Meet none of the exclusion criteria (any single exclusion criterion which is met by a potential subject will disqualify that subject from participation in this study).

Exclusion Criteria

  • Subjects will be considered NOT qualified for enrollment if they:
  • Have a history of dermatomyositis, systemic sclerosis, scleroderma, Sjögren's syndrome, systemic lupus erythematosis, discoid lupus, Ehler's Danlos disease, icthyosis vulgaris, vasculitis or bleeding disorders (coagulopathies).
  • Have any dermatologic disease which may be aggravated or provoked by the wounding procedure, such as Lichen Planus, Psoriasis or Vitiligo.
  • Have Fitzpatrick scale skin type 6 (never sunburns, deeply pigmented).
  • Are at risk of keloid or hypertrophic scar formation, based on personal history, family history, or brief skin exam (conducted at the screening visit to look for keloids or hypertrophic scars).
  • Have been treated within the last three months for uncontrolled diabetes mellitus, peripheral vascular disease, vitamin C deficiency, connective tissue disorders, or any other disease process that impedes wound healing.
  • Are taking concomitant medications at doses which are known to interfere with healing, such as non-steroidal anti-inflammatory drugs, anti-neoplastic drugs, or immunosuppressive drugs.
  • Are using topical glycolic acid products, alpha-hydroxy acid products, retinoids or chemical peel agents in the treatment areas.
  • Are using systemic steroids or immunosuppressant agents, or have used these drugs within the past three months.

Arms & Interventions

2

Placebo Comparator

Intervention: Placebo comparator

1

Xenaderm Vehicle

Intervention: Xenaderm Vehicle

Outcomes

Primary Outcomes

Complete Wound Closure

Time Frame: 21 Days

Each subject acting as their own control

Study Sites (1)

Loading locations...

Similar Trials